Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Haemorrhagic Disorders
Acquired coagulation disorders (including DIC)
Gene therapy
Haemophilia A and B
Haemophilia: therapy
Haemostatic agents
Immunology (including ITP and HIT)
Inherited coagulation disorders
Other haemmorrhagic disorders
Perinatal/pediatric haemostatis
Transfusion and storage
von Willebrand disease
von Willebrand factor
A patient with factor V Leiden who rapidly developed fatal heparin induced thrombocytopenia
Davidson S. J., Burman J. F., Chaubey S., Desouza A.
A systematic analysis of the effects of a thrombin-specific inhibitor, argatroban in HIT
Kelton J., Moore J. C., Santos A. V., Warkentin T. E.
Activation of neutrophils by antibodies generated in heparin-induced thrombocytopenia
Jeske W., Sinno S., Thoreson A., Prechel M. M., Walenga J. M.
Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT)
Greinacher A., Eichler P., Lubenow N.
Autoantibodies to recombinant PSI domain but not to cytoplasmic tail of beta3 integrin cause immune thrombocytopenia
Ni H., Chen P., Petruzziello T., Hynes R. O., Freedman J.
Benefit and risk of heparin addition in maintaining peripheral venous catheters in neonates – a prospective, double-blind, placebo-controlled trial
Klenner A., Fusch C., Rakow A., Beyersdorff E., Wander K., Lietz T., Eichler P., Greinacher A.
Bovine heparin results in higher generation of functional anti-heparin-PF4 antibodies than porcine heparin following coronary artery bypass surgery
Ahmad S., Drexler A., Reyes E., Meyer T. V., Palmer I. I. I., Moroose G. J. R., Francis J. L.
Cell lines expressing recombinant platelet membrane glycoprotein isoforms as tools for the characterization of antibodies against low frequency alloantigens in neonatal alloimmune thrombocytopenia
Kroll H., Yates J., Santoso S.
Changes in the platelet count (PC) after cardiopulmonary bypass (CPB) can efficiently predict the development of pathogenic heparin- dependent antibodies (Abs)
Gruel Y., Pouplard C., May M. A., Regina S., Maakaroun A., Fusciardi J.
Clinicopathological findings and response to treatment in childhood and adult immune thrombocytopenic purpura
Murari M., Sharma S., Pandey R.
Congenital afibrinogenemia: expression and analysis of novel mutations affecting fibrinogen assembly or secretion
Vu D., de Moerloose P., Abu-Libdeh B., Bouchardy I., Taher A., Bolton-Maggs P. H. B., Morris M. A., Neerman-Arbez M.
Cross-reactivity of anti-lepirudin antibodies from patients with heparin-induced thrombocytopenia with bivalirudin
Eichler P., Lubenow N., Strobel U., Greinacher A.
Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia
Gerdsen F., Wenning B., Bauersachs R., Lindhoff-Last E.
Drug-dependent antibodies are accompanied by drug-specific antibodies in Quinine-induced immune mediated thrombocytopenia
Bougie D., Wilker P. R., Aster R. H.
Drug-dependent antibodies, what binds where?
Bougie D., Wilker P. W., Birenbaum J. A., Aster R. H.
Economic evaluation of anti-D immunoglobulin in the treatment of immune thrombocytopenic purpura in adults in the United Kingdom
Sclar D., Skaer T. L., Evans M. A., Robison L. M., Chung K. C., Poulios N. S.
Endothelial cell damage as shown by raised soluble-thrombomodulin and total von Willebrand factor antigen levels during heparin induced thrombocytopenia
Davidson S. J., Burman J. F.
Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis
Francis J., Drexler A.
Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia
Sahud M.
Loss of tolerance for platelet glycoprotein VI by vaccination of Balb/c mice with a GPVI-tetanus toxoid fusion protein
Wilson E., Harmer I., Ouwehand W.
Maternal immunization against ‘rare’ platelet antigens as a cause of neonatal alloimmune thrombocytopenic purpura (NATP)
Peterson J. A., Balthazor S. M., Curtis B. R., Aster R. H.
PADA-HIT: A new POCT method for ultra-fast detection of HIT II antibodies
Nowak G., Schumann A., Wiesenburg A., Bucha E.
Partial results of the incidence of Thrombocytopenia Induced Heparin
Oliveira S. C., Rached R. A., Cavalheiro-Filho C., Chamone D. A. F.
Risk factors and long-term follow-up of patients with the immune type of heparin induced thrombocytopenia
Gerdsen F., Wenning B., Bauersachs R., Lindhoff-Last E.
Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II
Kamei M., Miyata S., Niwaya K., Bando K., Tsuji T., Suzuki S., Hanatani A., Ohnishi Y., Uchida O., Kuro M., Imanaka H., Kobayashi J., Yagihara T., Nakatani T.
Teicoplanin-dependent platelet antibodies as a cause of severe thrombocytopenia
Campbell K., Garner S. F., Hurd C., Davidson S., Burman J., Treacy M., Smith G., Ouwehand W. H.
The epitope of the CD109 monoclonal antibody 8A3 overlaps with the epitope of Gov antibodies: implications for Gov antibody detection
Smith G., Joutsi-Korhonen L., Haas De M., Berry J., Campbell K., Garner S., Schuh A., Watkins N., Ouwehand W. H.
The importance of repeat laboratory testing in the diagnosis of heparin-induced thrombocytopenia
Francis J., Drexler A.
The predictors of clinical outcome in patients with heparin-induced thombocytopenia
Kelton J., Hursting M. J., Lewis B. E.
Thrombin potential in heparin induced thrombocytopenia
Davidson S. J., Burman J. F., Wadham P.
Thrombocytopenia in HIV-infected patients, a report from HIV/AIDS Counseling and Care Center in Kermanshah, Iran
Alaei K., Alaei A., Davood M., Shaban A.
Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series
Zelcer S., Bussel J. B.
Trends in incidence and diagnosis of heparin-induced thrombocytopenia at a tertiary medical center
Francis J., Drexler A.